{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-016465","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2021-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.931793+00:00","generated_at":"2026-06-30T06:36:33.188246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biotricity issues preliminary Q1 FY2022 revenue guidance: up >45% QoQ","bullets":["Revenue for Q1 ended June 30, 2021 expected to increase >45% sequentially and >280% YoY.","This would be the 9th consecutive quarter of revenue growth.","Customer base expanded to 23 states from 17 states nine months ago.","CEO cites accelerating sequential growth, high correlation between devices and TaaS revenue.","Expects consistent triple-digit revenue growth for remainder of fiscal 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-016465","json":"https://secwatch.observer/filing/0001493152-21-016465.json","markdown":"https://secwatch.observer/filing/0001493152-21-016465.md","text":"https://secwatch.observer/filing/0001493152-21-016465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221016465/0001493152-21-016465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221016465/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T06:36:33.188246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}